Benztropine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: March 19, 2026

Benztropine

Ethers Of Tropine Or Tropine Derivatives

US FDACA Health Canada

Drug class: Ethers Of Tropine Or Tropine Derivatives
Availability: Prescription only
Routes: Oral, Intramuscular
Markets covered: 2
Products on record: 3

N04ACEthers Of Tropine Or Tropine Derivatives

Overview

Plain-language summary, compiled from the cited regulatory records

Benztropine is a medication classified as an ether of tropine or tropine derivative [1]. It is approved for use as an additional treatment for all types of parkinsonism [1]. Benztropine is also used to manage extrapyramidal disorders that can occur as a side effect of neuroleptic medications, such as phenothiazines [1]. However, it is not indicated for the treatment of tardive dyskinesia [1].

This medication is available in the market under various brand names [1].

This is not medical advice. Consult a qualified healthcare professional.

Regulatory status by market

Market	Regulator	Products	Last revision
US United States	FDA	2	March 19, 2026
CA Canada	Health Canada	1	March 22, 2025

USUnited States· FDA

2 products

Uses

USOfficial regulatory label· revised March 19, 2026[1]

INDICATIONS AND USAGE
Benztropine mesylate tablets, USP are indicated for use as an adjunct in the therapy of all forms of parkinsonism. , phenothiazines).

How to take

CACanada· Health Canada

1 product

1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].

Sources & citations

[1]FDA DailyMed · 01688e6f-7b22-41… · revised March 19, 2026 [PDF]
[2]Health Canada (DPD) · 02238903 · revised March 22, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

DOSAGE AND ADMINISTRATION
Benztropine mesylate tablets should be used when patients are able to take oral medication. The injection is especially useful for psychotic patients with acute dystonic reactions or other reactions that make oral medication difficult or impossible.
It is recommended also when a more rapid response is desired than can be obtained with the tablets. Because of cumulative action, therapy should be initiated with a low dose which is increased gradually at five or six-day intervals to the smallest amount necessary for optimal relief.
5 mg, to a maximum of 6 mg, or until optimal results are obtained without excessive adverse reactions. 5 to 6 mg orally or parentally. As with any agent used in parkinsonism, dosage must be individualized according to age and weight, and the type of parkinsonism being treated.
Generally, older patients, and thin patients cannot tolerate large doses. Most patients with postencephalitic parkinsonism need fairly large doses and tolerate them well. Patients with a poor mental outlook are usually poor candidates for therapy.
5 to 1 mg at bedtime. In some patients, this will be adequate; in others 4 to 6 mg a day may be required. In postencephalitic parkinsonism, therapy may be initiated in most patients with 2 mg a day in one or more doses. 5 mg at bedtime, and increased as necessary.
Some patients experience greatest relief by taking the entire dose at bedtime; others react more favorably to divided doses, two to four times a day. Frequently, one dose a day is sufficient, and divided doses may be unnecessary or undesirable.
The long duration of action of this drug makes it particularly suitable for bedtime medication when its effects may last throughout the night, enabling patients to turn in bed during the night more easily, and to rise in the morning.
When benztropine mesylate is started, do not terminate therapy with other antiparkinsonian agents abruptly. If the other agents are to be reduced or discontinued, it must be done gradually. Many patients obtain greatest relief with combination therapy.
Benztropine mesylate may be used concomitantly with Carbidopa-Levodopa, or with levodopa, in which case periodic dosage adjustment may be required in order to maintain optimum response. , phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day orally, or parenterally.
Dosage must be individualized according to the need of the patient. Some patients require more than recommended; others do not need as much. In acute dystonic reactions, 1 to 2 mL of the injection usually relieves the condition quickly.
After that, the tablets, 1 to 2 mg twice a day, usually prevents recurrence. , phenothiazines), they are likely to be transient. One to 2 mg of benztropine mesylate tablets two or three times a day usually provides relief within one or two days.
After one or two weeks, the drug should be withdrawn to determine the continued need for it. If such disorders recur, benztropine mesylate can be reinstituted. Certain drug-induced extrapyramidal disorders that develop slowly may not respond to benztropine mesylate.
CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088 OR LEADING PHARMA, LLC AT 1-844-740-7500.

Side effects & warnings

USOfficial regulatory label· Adverse reactions· revised March 19, 2026[1]

ADVERSE REACTIONS
The adverse reactions below, most of which are antichlolinergic in nature, have been reported and within each category are listed in order of decreasing severity. Cardiovascular Tachycardia. Digestive Paralytic ileus, constipation, vomiting, nausea, dry mouth.
If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily. Slight reduction in dosage may control nausea and still give sufficient relief of symptoms.
Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage. Nervous System Toxic psychosis, including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of preexisting psychotic symptoms; nervousness; depression; listlessness; numbness of fingers.
Special Senses Blurred vision, dilated pupils. Urogenital Urinary retention, dysuria. , skin rash, develops. If this cannot be controlled by dosage reduction, the medication should be discontinued. Other Heat stroke, hyperthermia, fever.

USOfficial regulatory label· Warnings and precautions· revised March 19, 2026[1]

WARNINGS
Safe use in pregnancy has not been established. Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly.
Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine mesylate, in combination with phenothiazines and/or tricyclic antidepressants.
Since benztropine mesylate contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment.
Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired.
Severe anhidrosis and fatal hyperthermia have occurred.

This is not medical advice. Consult a qualified healthcare professional.